openPR Logo
Press release

Lung Cancer Therapeutics Market Report Forecasting CAGR 12.4% Growth by 2026: Comprehensive Competitors Study By by Takeda Pharmaceutical Company Limited, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim International GmbH and others

05-13-2019 02:44 PM CET | Health & Medicine

Press release from: Data Bridge Market Research

Lung Cancer Therapeutics Market Report Forecasting CAGR 12.4%

The lung cancer can be categorized as an uncontrolled growth of cell in the lungs. The most common symptoms of this are cough, chest pain, weight loss, and shortness of breath. The lung cancer is the second most commonly diagnosed disease and has the highest mortality rate then others cancers. The major factors that cause lung cancer are cigarette smoking, pipes, cigar smoking, and constant exposure to asbestos. Due to rising demand for therapies such as targeted therapies that block the growth by targeting cancer-specific proteins, cells, and tissues that cause the cancer survival and division, without damaging the healthy cells. They are also proved to have higher efficiency over conventional therapies like platinum-based chemotherapy, surgical resection, and radiation therapy. According to article published recently by the WHO around 1.8 million cases of lung cancer were registered in the year 2012. According to the American Cancer Society, it has been estimated that in the U.S. around 195,000 people are suffering from NSCLC every year and the number of deaths from NSCLC are approximately 135,000. Increase in the death rate due to lung cancer has increased the need for lung cancer therapeutics.

Lung cancer is type of cancer which decreases the efficiency of lungs to supply oxygen to the bloodstream. This is one of the most common forms of cancers which accounts for the highest mortality rates. The lung cancer can be categorized as an uncontrolled growth of cell in the lungs. The main cause of lung cancers is pipes, cigarette smoking, cigar smoking, and asbestos exposure. Almost around 80.0% of the total lung cancers are non-small cell lung cancer. This kind of cancer is distinguished by their size as they are seen under the microscope. The most common symptoms of lung cancer are coughing, weight loss, chest pains, and shortness of breath. Lung cancers can be treated by various types of therapies like vaccines, radiation therapy, chemotherapy, and immunotherapies.

Market Analysis:
Global lung cancer therapeutics market is expected to register a CAGR of 12.4% in the forecast period of 2019 to 2026.

Download Sample PDF Report https://databridgemarketresearch.com/request-a-sample/?dbmr=global-lung-cancer-therapeutics-market

Major Market Competitors/Players
Some of the major players operating in the global lung cancer therapeutics market are Roche, AstraZeneca Plc, Agennix AG, Eli Lilly and Company, Merck, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Boehringer Ingelheim GmbH, and Hoffman-La Roche, F. Hoffmann-La Roche, Boehringer Ingelheim GmbH, Pfizer Inc., Sanofi-Aventis, and Celgene Corporation, Sanofi, Merck & Co., Inc among others.

Research Methodology:
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

Product Launch
• In November 2018, Johnson & Johnson and Janssen Biotech(U.S.) launched a potentially more than USD 1.255 billion collaboration with Seoul-based Yuhan Corporation (South Korea) for the development of its non-small cell lung cancer (NSCLC) drug, Lazertinib. This drug is now under study in an ongoing Phase I/II trial in South Korea. The new product launch will increase the company’s product line for the lung cancer treatment.
• In April 2018, F. Hoffmann-La Roche Ltd has launched Tecentriq in India which can be used for two types of cancers – urothelial carcinoma and non-small cell lung cancer (NSCLC). This will give the company to expand their market in Indian market.

Get Detailed TOC https://databridgemarketresearch.com/toc/?dbmr=global-lung-cancer-therapeutics-market

Major Market Drivers and Restraints:
Increasing incidences of lung cancer due to rising smoking population.
Players are adopting various strategies to expand their product portfolio
Growing demand for targeted therapies, presence of highly efficient drugs, increase in geriatric population, and rise in the prevalence of unhealthy lifestyles.
Poor cancer diagnostic facilities in many developing countries.
Limited options for treatment, and the vast unmet requirement for diagnosis

Segmentation: Global Lung Cancer Therapeutics Market
Global lung cancer therapeutics market is segmented into seven notable segments which are cancer
• Type
• molecule type
• drug class
• treatment type
• therapy type
• end user
• distribution channel

On the basis of cancer type, the market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumors, pulmonary neuroendocrine tumors, mediastinal tumors. In 2019, non-small cell lung cancer is expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In March 2019, FDA approved the Roche’s Tecentriq in combination with the chemotherapy for initially treating adults with an extensive stage of small cell lung cancer. This would help company to enhance its customer base.

On the basis of molecule type, the market is segmented into small molecules, biologics. In 2019, small molecules are expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In January 2019, Bristol-Myers Squibb is entered into an agreement to acquire Celgene (U.S.). With this acquisition Bristol-Myers Squibb is able to create a premier innovative biopharma company which will increase the company’s product line for the lung cancer therapeutics market.

On the drug class, the market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors, others. In 2019, antimetabolites are expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In October 2018, Bristol-Myers Squibb and Compugen (Canada) has entered into a clinical collaboration for the evaluation of therapeutic regimen in advanced solid tumor. This will help the company to strengthen their market presence.

On the basis of treatment type, the market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs. In 2019, targeted therapy is expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In July 2017, AstraZeneca and MedImmune, which is its global biologics R&D arm announced that the FDA granted a Breakthrough Therapy Designation for the Imfinzi (durvalumab) for treating patients with locally advanced and unresectable NSCLC, whose disease did not progressed after the platinum based chemoradiation therapy. This would help in the expansion of the product portfolio of the company.

On the basis of therapy type, the market is segmented into single drug therapy, combination therapy. In 2019, combination therapy is expected to be growing at the CAGR in the forecast period of 2019 to 2026.
• In January 2019, the company announced that the U.S. Food and Drug Administration has granted approval for the new indication for ALIMTA in combination with the KEYTRUDA which is marketed and developed by Merck and platinum chemotherapy for treating the people with metastatic nonsquamous NSCLC, with no ALK genomic or EGFR tumor aberrations. This will create a landmark for the company and with this the company will be able to market their product in the U.S. market.

On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others. In 2019, homecare is expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In January 2018, European Commission approved Amgen and Allergan’s MVASI (Biosimilar Bevacizumab) which can be used for the treatment of certain types of cancer. This drug can be used for the treatment of metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) or this can be used in the treatment of metastatic or recurrent non-squamous NSCLC when it is given in the combination with erlotinib. This drug can be launch will give a significant milestone to the company as this is used for a variety of cancer treatments.

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online and others. In 2019, hospital pharmacy is expected to be growing at the highest CAGR in the forecast period of 2019 to 2026.
• In January 2019, the company entered into a merger agreement with the Bristol-Myers Squibb Company under which the Bristol-Myers Squibb will be acquiring Celgene in a stock and cash transaction with the equity value of around USD 7400 million. This would help in the expansion of the product portfolio of the companies.

Speak to Author https://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-lung-cancer-therapeutics-market

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate

Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lung Cancer Therapeutics Market Report Forecasting CAGR 12.4% Growth by 2026: Comprehensive Competitors Study By by Takeda Pharmaceutical Company Limited, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim International GmbH and others here

News-ID: 1737010 • Views:

More Releases from Data Bridge Market Research

Aquaculture Products Market Size, Share, Trends, Key Drivers, Growth Opportuniti …
Aquaculture Products Market business report provides a profound overview of product specification, technology, product type and production analysis considering major factors such as revenue, cost, and gross margin. The data and information collected to generate this top-notch market report has been derived from the trusted sources such as company websites, white papers, journals, and mergers etc. Aquaculture Products Market report includes basic, secondary and advanced information related to the global
Hydrochloric Acid Market Size, Share, Trends, Demand, Future Growth, Challenges …
Data Bridge Market research has recently released expansive research titled Global Hydrochloric Acid Market  guarantees you will remain better informed than your competition.The report is formulated based on the market type, organization size, availability on-premises, the end-users' organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. Businesses can accomplish knowledge about complete background analysis of the industry which includes
Electrostatic Disinfectant Sprayer Market Size, Share, Demand, Future Growth, Ch …
Global Electrostatic Disinfectant Sprayer Market report puts light on analysis of prime manufacturers, trends, opportunities, marketing strategies analysis, market effect factor analysis and consumer needs by major regions, types, and applications globally. The study offers a comprehensive analysis of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments. The data and information covered in the Electrostatic Disinfectant Sprayer report are obtained from reliable sources
Paint Protection Film Market Size, Share, Trends, Opportunities, Key Drivers and …
Global Paint Protection Film Market study by Data Bridge Market Research provides details about the market dynamics affecting this market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years. The latest market data has been presented in the Paint Protection Film market study on the revenue numbers, product details, and sales of the major firms. In addition

All 5 Releases


More Releases for CAGR

Cat Litter Box Market | CAGR of 9.1% | Revenue & CAGR of 9.1%
Cat Litter Box Market Report provides precise data about the market size, commercialization aspects and revenue forecast of the industry. The global Cat Litter Box market offers a historical factsheet relevant to the strategic mergers, acquirements, joint venture activities, and partnerships spread in the Cat Litter Box market. The most advanced data has been presented in the study on the revenue numbers, product details, and sales of the major firms.
Predictive Analytics Market Growing at Strong CAGR of CAGR of 25.31% 2019
Predictive analytics helps to extract information from the existing data. It helps in understanding the pattern and predict the trend or future for the organization. It uses what-if scenarios to predict possible risks involved in the future. Predictive analytics also helps in the optimization of the marketing campaigns and understanding of the customer behaviour for increasing the end-user response and to reduce the churn. Predictive analytics is segmented into: Risk management:
Global Absorption Chillers Market Reflecting a CAGR of 7.6% CAGR through 2025
The demand for thermally-driven chillers in multiple industrial verticals is poised to grow in the immediate future. Considering the rising demand for electrical chillers in commercial, residential as well as industrial settings, the adoption of absorption chillers will gain traction at considerable rate. By consuming lesser energy than conventional electrical chillers, absorption chillers will also garner surplus demand for not using ozone-depleting chlorofluorocarbons (CFC) for chilling purposes. Persistence Market Research’s
Aircraft Sensors Market Growing at a CAGR of 6.4% CAGR By 2022
The global aircraft sensors market is forecasted to receive a strong push in its growth momentum on the back of advancements in technologies, massive investments forwarded by private equity groups, and the elevation in the demand for aircraft. Adherence to the requirements and regulations of authorities such as local aircraft regulatory bodies and the Federal Aviation Administration (FAA) could pamper the growth of the market. Nonetheless, there could be more
China Baby Diapers Market Reflecting a CAGR of 19.1% CAGR 2012-2017
The increasing birth rate in China has proven to be a boon for the country’s baby diaper’s market. To provide a comprehensive analysis of the growth trajectory exhibited by the China baby diapers market and study the impact of the dynamic regulatory policies on the market, Transparency Market Research (TMR) has published a report, titled “Baby Diapers Market - China Industry Analysis, Market Size, Share, Growth, Trends And Forecast, 2012
Ecg Device Market Register a CAGR Growth of 4.1% CAGR by 2024
This region holds highest market share over the forecast period (2016-2024) and is expected to exhibit slow growth rate. The Asia Pacific is expected to be the fastest-growing region for ECG devices owing to its increasing incidence rate of cardiovascular diseases and high population. ECG devices are experiencing a paradigm technological shift from resting ECG systems to portable Holter monitoring systems, owing to their advantages of patient mobility, low prices and